Literature DB >> 11290475

Enhancing patterns in multiple sclerosis: evolution and persistence.

J He1, R I Grossman, Y Ge, L J Mannon.   

Abstract

BACKGROUND AND
PURPOSE: Contrast enhancement on MR images of patients with multiple sclerosis (MS) is known to be associated with abnormalities of the blood-brain barrier (BBB). However, little is known about diagnostic patterns and common features of enhanced MS lesions. This study was designed to evaluate initial enhancement patterns, changes in these enhancing patterns, and duration of enhancement in a cohort of patients with MS.
METHODS: Twenty-five patients with clinically definite MS were studied retrospectively. The appearance of enhancing lesions and sequential changes in the appearance on axial contrast-enhanced spin-echo images were evaluated. The enhancing lesions were classified as nodular, ringlike, or "other" (eg, arclike).
RESULTS: Of 301 new enhancing lesions, 205 (68%) showed nodular enhancement, 70 (23%) a ring pattern, and 26 (9%) a pattern neither nodular nor ringlike (eg, arclike). Two hundred eighty (93%) of 301 enhancing lesions disappeared within 6 months, and seven (2%) lesions showed persistent enhancement longer than 6 months. The other 14 (5%) lesions, which disappeared by the time of the next scan, were excluded, because the course between two examinations was longer than 6 months. Of nine persisting nodular enhancing lesions on the follow-up images, seven were decreased in size, whereas all of two persisting ringlike enhancing lesions on the follow-up images were larger than before.
CONCLUSION: Nodular enhancement is the predominant enhancement pattern for new MS lesions, and the temporal course of enhancement is usually shorter than 6 months. The appreciation of the evolution of MS-enhanced lesions aids in both identifying new MS lesions and distinguishing these lesions from other pathologic entities. This may be helpful in clinically evaluating the stage of MS lesions.

Entities:  

Mesh:

Year:  2001        PMID: 11290475      PMCID: PMC7976005     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  31 in total

1.  Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging.

Authors:  M Filippi; M A Rocca; M P Sormani; C Pereira; G Comi
Journal:  Magn Reson Imaging       Date:  1999-09       Impact factor: 2.546

2.  The longstanding MS lesion. A quantitative MRI and electron microscopic study.

Authors:  D Barnes; P M Munro; B D Youl; J W Prineas; W I McDonald
Journal:  Brain       Date:  1991-06       Impact factor: 13.501

3.  Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.

Authors:  J O Harris; J A Frank; N Patronas; D E McFarlin; H F McFarland
Journal:  Ann Neurol       Date:  1991-05       Impact factor: 10.422

4.  Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability.

Authors:  M Filippi; P Rossi; A Campi; B Colombo; C Pereira; G Comi
Journal:  AJNR Am J Neuroradiol       Date:  1997-09       Impact factor: 3.825

5.  Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images.

Authors:  A Rovira; J Alonso; G Cucurella; C Nos; M Tintoré; S Pedraza; J Rio; X Montalban
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

6.  Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans.

Authors:  M Rovaris; G Mastronardo; F Prandini; S Bastianello; G Comi; M Filippi
Journal:  J Neurol Sci       Date:  1999-04-01       Impact factor: 3.181

7.  Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect.

Authors:  J R Petrella; R I Grossman; J C McGowan; G Campbell; J A Cohen
Journal:  AJNR Am J Neuroradiol       Date:  1996 Jun-Jul       Impact factor: 3.825

8.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

Authors:  M Filippi; T Yousry; A Campi; C Kandziora; B Colombo; R Voltz; V Martinelli; S Spuler; S Bressi; G Scotti; G Comi
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

9.  Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

Authors:  L Kappos; D Moeri; E W Radue; A Schoetzau; K Schweikert; F Barkhof; D Miller; C R Guttmann; H L Weiner; C Gasperini; M Filippi
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

Review 10.  The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis.

Authors:  F Fazekas; F Barkhof; M Filippi; R I Grossman; D K Li; W I McDonald; H F McFarland; D W Paty; J H Simon; J S Wolinsky; D H Miller
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

View more
  24 in total

1.  Longitudinal multiple sclerosis lesion segmentation: Resource and challenge.

Authors:  Aaron Carass; Snehashis Roy; Amod Jog; Jennifer L Cuzzocreo; Elizabeth Magrath; Adrian Gherman; Julia Button; James Nguyen; Ferran Prados; Carole H Sudre; Manuel Jorge Cardoso; Niamh Cawley; Olga Ciccarelli; Claudia A M Wheeler-Kingshott; Sébastien Ourselin; Laurence Catanese; Hrishikesh Deshpande; Pierre Maurel; Olivier Commowick; Christian Barillot; Xavier Tomas-Fernandez; Simon K Warfield; Suthirth Vaidya; Abhijith Chunduru; Ramanathan Muthuganapathy; Ganapathy Krishnamurthi; Andrew Jesson; Tal Arbel; Oskar Maier; Heinz Handels; Leonardo O Iheme; Devrim Unay; Saurabh Jain; Diana M Sima; Dirk Smeets; Mohsen Ghafoorian; Bram Platel; Ariel Birenbaum; Hayit Greenspan; Pierre-Louis Bazin; Peter A Calabresi; Ciprian M Crainiceanu; Lotta M Ellingsen; Daniel S Reich; Jerry L Prince; Dzung L Pham
Journal:  Neuroimage       Date:  2017-01-11       Impact factor: 6.556

2.  Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?

Authors:  Constantina Andrada Treabă; Rodica Bălaşa; Daniela Maria Podeanu; Iunius Paul Simu; Mircea Marian Buruian
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

3.  Interactions and tradeoffs between cell recruitment, proliferation, and differentiation affect CNS regeneration.

Authors:  William R Holmes; Qing Nie
Journal:  Biophys J       Date:  2014-04-01       Impact factor: 4.033

4.  Gadolinium-Enhanced Susceptibility-Weighted Imaging in Multiple Sclerosis: Optimizing the Recognition of Active Plaques for Different MR Imaging Sequences.

Authors:  L L F do Amaral; D C Fragoso; R H Nunes; I A Littig; A J da Rocha
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

Review 5.  Multiple sclerosis: the role of MR imaging.

Authors:  Y Ge
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

6.  Tumefactive demyelination-to cracks the nut without cracking the pot.

Authors:  C Rajasekharan; V Anto; R Unnikrishnan
Journal:  BMJ Case Rep       Date:  2012-03-08

7.  Cerebral tumefactive demyelinating lesions.

Authors:  Wei Qi; G E Jia; Xinsheng Wang; Maozhi Zhang; Zhenyu Ma
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

8.  Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions.

Authors:  María I Gaitán; Colin D Shea; Iordanis E Evangelou; Roger D Stone; Kaylan M Fenton; Bibiana Bielekova; Luca Massacesi; Daniel S Reich
Journal:  Ann Neurol       Date:  2011-06-27       Impact factor: 10.422

9.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

Review 10.  Tumefactive demyelinating lesions: nine cases and a review of the literature.

Authors:  Lei Xia; Song Lin; Zhong-cheng Wang; Shao-wu Li; Li Xu; Jing Wu; Shu-yu Hao; Chuan-chuan Gao
Journal:  Neurosurg Rev       Date:  2009-01-27       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.